Proteomics International Laboratories Ltd – CMS Sets Reimbursement Price for PromarkerD
Proteomics International Laboratories Ltd (ASX: PIQ) has confirmed a national reimbursement price of US$390.75 for Proteomics International’s next-generation PromarkerD predictive test, marking a pivotal milestone ahead of its expanded US rollout in 2026. Supported by an AMA-assigned PLA code, the pricing decision provides a dedicated billing pathway and strengthens negotiations with private insurers, who commonly adopt CMS benchmarks when determining their own reimbursement policies.
PromarkerD, currently offered through the company’s CLIA-certified California laboratory, can identify patients with type 2 diabetes at risk of diabetic kidney disease up to four years before clinical symptoms emerge, allowing earlier use of renal-protective therapies. With over 32 million US adults living with diabetes and diabetic kidney disease costs surpassing US$130 billion annually, the test offers meaningful potential to reduce healthcare expenditure and improve long-term patient outcomes. CMS’s determination reinforces PromarkerD’s clinical value and supports broader commercial uptake.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Proteomics International Laboratories Ltd – CMS Sets Reimbursement Price for PromarkerD
Proteomics International Laboratories Ltd (ASX: PIQ) has confirmed a national reimbursement price of US$390.75 for Proteomics International’s next-generation PromarkerD predictive test, marking a pivotal milestone ahead of its expanded US rollout in 2026. Supported by an AMA-assigned PLA code, the pricing decision provides a dedicated billing pathway and strengthens negotiations with private insurers, who commonly adopt CMS benchmarks when determining their own reimbursement policies.
PromarkerD, currently offered through the company’s CLIA-certified California laboratory, can identify patients with type 2 diabetes at risk of diabetic kidney disease up to four years before clinical symptoms emerge, allowing earlier use of renal-protective therapies. With over 32 million US adults living with diabetes and diabetic kidney disease costs surpassing US$130 billion annually, the test offers meaningful potential to reduce healthcare expenditure and improve long-term patient outcomes. CMS’s determination reinforces PromarkerD’s clinical value and supports broader commercial uptake.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au